+

WO2003068776A1 - Derives de (1, 2, 4) triazolo (1,5-c) pyrimidine - Google Patents

Derives de (1, 2, 4) triazolo (1,5-c) pyrimidine Download PDF

Info

Publication number
WO2003068776A1
WO2003068776A1 PCT/JP2003/001565 JP0301565W WO03068776A1 WO 2003068776 A1 WO2003068776 A1 WO 2003068776A1 JP 0301565 W JP0301565 W JP 0301565W WO 03068776 A1 WO03068776 A1 WO 03068776A1
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
triazolo
pyrimidine derivatives
adenosine
receptor
Prior art date
Application number
PCT/JP2003/001565
Other languages
English (en)
Japanese (ja)
Inventor
Hironori Imma
Tomokazu Watanabe
Shizuo Shiozaki
Tomoyuki Kanda
Yoshihisa Kuwana
Junichi Shimada
Original Assignee
Kyowa Hakko Kogyo Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co., Ltd. filed Critical Kyowa Hakko Kogyo Co., Ltd.
Priority to AU2003211993A priority Critical patent/AU2003211993A1/en
Priority to JP2003567903A priority patent/JPWO2003068776A1/ja
Publication of WO2003068776A1 publication Critical patent/WO2003068776A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des dérivés de (1, 2, 4) triazolo (1,5-c)pyrimidine représentés par la formule générale suivante (I) ou des sels pharmacologiquement acceptables de ces derniers. Ces composés présentent un antagonisme du récepteur A2A de l'adénosine, et sont utiles pour traiter et/ou prévenir diverses maladies provoquées par l'hyperfonctionnement du récepteur A2A de l'adénosine. Dans la formule, R1 représente un aryl éventuellement substitué ou de l'hétéroaryl optionnellement substitué ; R2 représente de l'hydrogène, de l'halogéno, de l'alkyle inférieur éventuellement substitué ; et R3 représente un groupe de l'une des formules suivantes (A), (B) et (C).
PCT/JP2003/001565 2002-02-15 2003-02-14 Derives de (1, 2, 4) triazolo (1,5-c) pyrimidine WO2003068776A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2003211993A AU2003211993A1 (en) 2002-02-15 2003-02-14 (1,2,4)TRIAZOLO(1,5-c)PYRIMIDINE DERIVATIVES
JP2003567903A JPWO2003068776A1 (ja) 2002-02-15 2003-02-14 ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002-37819 2002-02-15
JP2002037819 2002-02-15

Publications (1)

Publication Number Publication Date
WO2003068776A1 true WO2003068776A1 (fr) 2003-08-21

Family

ID=27678133

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2003/001565 WO2003068776A1 (fr) 2002-02-15 2003-02-14 Derives de (1, 2, 4) triazolo (1,5-c) pyrimidine

Country Status (3)

Country Link
JP (1) JPWO2003068776A1 (fr)
AU (1) AU2003211993A1 (fr)
WO (1) WO2003068776A1 (fr)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004029056A1 (fr) * 2002-09-24 2004-04-08 Kyowa Hakko Kogyo Co., Ltd. Dérivé de [1,2,4]-triazolo[1,5]pyrimidine
WO2004092173A3 (fr) * 2003-04-09 2004-12-09 Biogen Idec Inc Antagonistes de recepteur d'adenosine a2a
US7285550B2 (en) 2003-04-09 2007-10-23 Biogen Idec Ma Inc. Triazolotriazines and pyrazolotriazines and methods of making and using the same
US7517874B2 (en) 2007-06-21 2009-04-14 Cara Therapeutics, Inc. Substituted imidazo[1,5-a][1,4]diazepines and imidazo[1,5-a]pyrazines as cannabinoid receptor agonists for the treatment of pain
US7674791B2 (en) 2003-04-09 2010-03-09 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
US8071766B2 (en) 2008-02-01 2011-12-06 Takeda Pharmaceutical Company Limited HSP90 inhibitors
US8859538B2 (en) 2007-06-21 2014-10-14 Cara Therapeutics, Inc. Uses of substituted imidazoheterocycles
CN107922437A (zh) * 2015-09-09 2018-04-17 豪夫迈·罗氏有限公司 桥连哌啶衍生物
WO2018166493A1 (fr) * 2017-03-16 2018-09-20 江苏恒瑞医药股份有限公司 Dérivé d'hétéroaryl[4,3-c]pyrimidine-5-amine, son procédé de préparation et ses utilisations médicales
WO2020106558A1 (fr) 2018-11-20 2020-05-28 Merck Sharp & Dohme Corp. Amino-triazolopyrimidine et amino-triazolopyrazine substitués antagoniste du récepteur de l'adénosine, compositions pharmaceutiques et leur utilisation
US11161850B2 (en) 2018-07-05 2021-11-02 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
US11168089B2 (en) 2018-05-18 2021-11-09 Incyte Corporation Fused pyrimidine derivatives as A2A / A2B inhibitors
US11390624B2 (en) 2019-01-29 2022-07-19 Incyte Corporation Pyrazolopyridines and triazolopyridines as A2A / A2B inhibitors
WO2022224180A1 (fr) * 2021-04-23 2022-10-27 Chong Kun Dang Pharmaceutical Corp. Composé constituant un antagoniste du récepteur a2a de l'adénosine et composition pharmaceutique le comprenant
US11673894B2 (en) 2018-02-27 2023-06-13 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
RU2802866C2 (ru) * 2018-09-12 2023-09-05 Дизал (Цзянсу) Фармасьютикал Ко., Лтд. Соединения триазоло-пиримидина и их применение
US12043623B2 (en) 2015-11-20 2024-07-23 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998042711A1 (fr) * 1997-03-24 1998-10-01 Kyowa Hakko Kogyo Co., Ltd. DERIVES [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINIQUES
WO2000017201A1 (fr) * 1998-09-22 2000-03-30 Kyowa Hakko Kogyo Co., Ltd. DERIVES DE [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998042711A1 (fr) * 1997-03-24 1998-10-01 Kyowa Hakko Kogyo Co., Ltd. DERIVES [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINIQUES
WO2000017201A1 (fr) * 1998-09-22 2000-03-30 Kyowa Hakko Kogyo Co., Ltd. DERIVES DE [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004029056A1 (fr) * 2002-09-24 2004-04-08 Kyowa Hakko Kogyo Co., Ltd. Dérivé de [1,2,4]-triazolo[1,5]pyrimidine
WO2004092173A3 (fr) * 2003-04-09 2004-12-09 Biogen Idec Inc Antagonistes de recepteur d'adenosine a2a
US7285550B2 (en) 2003-04-09 2007-10-23 Biogen Idec Ma Inc. Triazolotriazines and pyrazolotriazines and methods of making and using the same
US7674791B2 (en) 2003-04-09 2010-03-09 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
US7834014B2 (en) 2003-04-09 2010-11-16 Biogen Idec Ma Inc. A2a adenosine receptor antagonists
US7517874B2 (en) 2007-06-21 2009-04-14 Cara Therapeutics, Inc. Substituted imidazo[1,5-a][1,4]diazepines and imidazo[1,5-a]pyrazines as cannabinoid receptor agonists for the treatment of pain
US8431565B2 (en) 2007-06-21 2013-04-30 Cara Therapeutics, Inc. Substituted imidazoheterocycles
US8859538B2 (en) 2007-06-21 2014-10-14 Cara Therapeutics, Inc. Uses of substituted imidazoheterocycles
US8071766B2 (en) 2008-02-01 2011-12-06 Takeda Pharmaceutical Company Limited HSP90 inhibitors
US8618290B2 (en) 2008-02-01 2013-12-31 Takeda Pharmaceutical Company Limited HSP90 inhibitors
CN107922437A (zh) * 2015-09-09 2018-04-17 豪夫迈·罗氏有限公司 桥连哌啶衍生物
US12043623B2 (en) 2015-11-20 2024-07-23 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors
JP7111733B2 (ja) 2017-03-16 2022-08-02 江蘇恒瑞医薬股▲ふん▼有限公司 ヘテロアリール［４，３－ｃ］ピリミジン－５－アミン誘導体、その製造方法、およびその医薬の使用
JP2020510012A (ja) * 2017-03-16 2020-04-02 江蘇恒瑞医薬股▲ふん▼有限公司 ヘテロアリール［４，３−ｃ］ピリミジン−５−アミン誘導体、その製造方法、およびその医薬の使用
WO2018166493A1 (fr) * 2017-03-16 2018-09-20 江苏恒瑞医药股份有限公司 Dérivé d'hétéroaryl[4,3-c]pyrimidine-5-amine, son procédé de préparation et ses utilisations médicales
TWI772386B (zh) 2017-03-16 2022-08-01 大陸商江蘇恆瑞醫藥股份有限公司 雜芳基并[4,3-c]嘧啶-5-胺類衍生物、其製備方法及其在醫藥上的使用
RU2764655C2 (ru) * 2017-03-16 2022-01-19 Цзянсу Хэнжуй Медицин Ко., Лтд. ПРОИЗВОДНОЕ ГЕТЕРОАРИЛ[4,3-с]ПИРИМИДИН-5-АМИНА, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО МЕДИЦИНСКИЕ ПРИМЕНЕНИЯ
US11312705B2 (en) 2017-03-16 2022-04-26 Jiangsu Hengrui Medicine Co., Ltd. Heteroaryl[4,3-C]pyrimidine-5-amine derivative, preparation method therefor, and medical uses thereof
US11673894B2 (en) 2018-02-27 2023-06-13 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
US11168089B2 (en) 2018-05-18 2021-11-09 Incyte Corporation Fused pyrimidine derivatives as A2A / A2B inhibitors
US11873304B2 (en) 2018-05-18 2024-01-16 Incyte Corporation Fused pyrimidine derivatives as A2A/A2B inhibitors
US11161850B2 (en) 2018-07-05 2021-11-02 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
US11999740B2 (en) 2018-07-05 2024-06-04 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
RU2802866C9 (ru) * 2018-09-12 2023-10-16 Дизал (Цзянсу) Фармасьютикал Ко., Лтд. Соединения триазоло-пиримидина и их применение
RU2802866C2 (ru) * 2018-09-12 2023-09-05 Дизал (Цзянсу) Фармасьютикал Ко., Лтд. Соединения триазоло-пиримидина и их применение
WO2020106558A1 (fr) 2018-11-20 2020-05-28 Merck Sharp & Dohme Corp. Amino-triazolopyrimidine et amino-triazolopyrazine substitués antagoniste du récepteur de l'adénosine, compositions pharmaceutiques et leur utilisation
EP3883575A4 (fr) * 2018-11-20 2022-06-15 Merck Sharp & Dohme Corp. Amino-triazolopyrimidine et amino-triazolopyrazine substitués antagoniste du récepteur de l'adénosine, compositions pharmaceutiques et leur utilisation
US11884665B2 (en) 2019-01-29 2024-01-30 Incyte Corporation Pyrazolopyridines and triazolopyridines as A2A / A2B inhibitors
US11390624B2 (en) 2019-01-29 2022-07-19 Incyte Corporation Pyrazolopyridines and triazolopyridines as A2A / A2B inhibitors
WO2022224180A1 (fr) * 2021-04-23 2022-10-27 Chong Kun Dang Pharmaceutical Corp. Composé constituant un antagoniste du récepteur a2a de l'adénosine et composition pharmaceutique le comprenant
RU2840068C2 (ru) * 2021-04-23 2025-05-16 Чонг Кун Данг Фармасьютикал Корп. СОЕДИНЕНИЕ В КАЧЕСТВЕ АНТАГОНИСТА АДЕНОЗИНОВОГО РЕЦЕПТОРА A2a И СОДЕРЖАЩАЯ ЕГО ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ

Also Published As

Publication number Publication date
AU2003211993A1 (en) 2003-09-04
JPWO2003068776A1 (ja) 2005-06-02

Similar Documents

Publication Publication Date Title
WO2003035639A1 (fr) Compose de pyrimidine et composition medicinale contenant ledit compose
WO2003068776A1 (fr) Derives de (1, 2, 4) triazolo (1,5-c) pyrimidine
EP1700856A4 (fr) Derive de thiazole
DE69820866D1 (de) [1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-DERIVATE
EP1505068A4 (fr) DERIVE DE PYRAZOLO(1,5-a)PYRIMIDINE ET INHIBITEUR DE LA NAD(P)H OXYDASE CONTENANT LEDIT DERIVE
WO2004056827A3 (fr) Derives de pyrrolo-pyrazoles substitues constituant des inhibiteurs de kinases
DK1401837T3 (da) Purinderivater som A2B-adenosinreceptorantagonister
EP2258372B8 (fr) L'utilisation des antagonistes des récepteurs A2A pour le treaitment de troubles de motricité
NO20063231L (no) Pyrido[2,3-D]pyrimidin-2,4-diaminer som PDE 2 inhibitorer
DE502004007000D1 (de) Stickstoff substituierte hexahydro-pyrazino 1,2-a pyrimidin-4,7-dionderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
NO20064166L (no) Utvalgte CGRP-antagonister, deres fremstilling og deres anvendelse som medikanmenter
PT1159279E (pt) 4-oxo-4,7-di-hidrotieno¬2,3-b|piridino-5-carboxamidas como agentes antivirais
DE60130562D1 (de) Azaindolderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel
AU2003215753A1 (en) Imidazopyridine derivatives as kinase inhibitors
WO2007143705A3 (fr) Composés organiques
WO2005060972A3 (fr) Methode pour traiter le rejet de greffe
DE502004011328D1 (de) Substituierte hexahydro-pyrazino(1,2-a)pyrimidin-4,7-dionderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
NO20055510L (no) 2-alkynyl- og 2-alkenylpyrazolo [4,3-E]-1,2,4-triazolo-[1,5-C]-pyrimidin-adenosin A2A-reseptorantagonister
TWI349674B (en) Derivatives of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl]phosphonic acid and methods of use thereof
ATE359791T1 (de) Pyrimidin-2,4-dion-derivate als matrix- metalloproteinase-hemmer
DK1534707T3 (da) Substituerede 2,4-dihydropyrrolo[3,4-b]quinolin-9-on-derivater egnede som phosphodiesteraseinhibitorer
EP1477490A4 (fr) Derive pyrrolopyrimidine
WO2003008365A3 (fr) Derives de phenylacetamido-thiazole, leur procede de preparation et leur utilisation en tant qu'agents antitumoraux
WO2000059449A3 (fr) Derives de purine possedant une activite d'inhibition de la phosphodiesterase iv
BR0115121A (pt) Compostos n-((1,2,4)triazoloazinil)tiofenossulfonamida como herbicidas

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003567903

Country of ref document: JP

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载